SynthesisScientific reports2026
EQ-5D outcomes in adults with autoimmune hepatitis: A GRADE-assessed systematic review and meta-analysis.
Synthesis in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune hepatitis (AIH) is a chronic immune-mediated liver disease that can substantially affect health-related quality of life (HRQoL). Although EQ-5D is widely used as a generic preference-based HRQoL instrument, EQ-5D outcomes in adults with AIH have not previously been synthesized in a focused systematic review. This review aimed to summarize EQ-5D outcomes in adults with AIH and assess the certainty of the available evidence using GRADE. A systematic review and meta-analysis was conducted in accordance with PRISMA and prospectively registered in PROSPERO (CRD420261334849). PubMed/MEDLINE, Scopus, Embase, and CENTRAL were searched from inception to 25 February 2026. Studies reporting EQ-5D utility/index, EQ-VAS, and/or domain-level outcomes in adults with AIH were included. Qualitative synthesis served as the primary interpretive framework, and quantitative synthesis was performed as an exploratory summary when appropriate. Certainty of evidence was assessed using GRADE. Five studies were included. Reported EQ-5D utility values ranged from 0.65 to 0.88, and EQ-VAS values ranged from 67.5 to 77.3 across studies. Exploratory random-effects synthesis yielded a pooled EQ-5D utility estimate of 0.80 (95% CI: 0.71 to 0.89; I² = 99.3%) and a pooled EQ-VAS estimate of 70.87 (95% CI: 67.28 to 74.46; I² = 93.9%). However, these pooled values should be interpreted as descriptive summaries of a highly heterogeneous evidence base rather than as stable benchmark estimates. Domain-level data from two studies suggested that pain/discomfort and anxiety/depression were the most frequently affected EQ-5D dimensions. Certainty of evidence was very low for all synthesized outcome groups. Available EQ-5D evidence in adults with AIH suggests an important HRQoL burden, particularly in the pain/discomfort and anxiety/depression domains. However, the evidence base is sparse, highly heterogeneous, and of very low certainty; therefore, pooled EQ-5D and EQ-VAS values should be interpreted as exploratory descriptive summaries rather than definitive benchmark estimates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.